Seeking Alpha

jamack22 » Comments |

Sort by:
Latest | Highest rated
  • Rich Pzena: A Working Man's Buffett [View article]
    is this the same rich pzena that still owns Freddiemac and Fannie Mae>
    May 02 23:16 pm |Rating: 0 0 |Link to Comment
  • Dendreon: Bear Trap of the Year [View article]
    : Two execs in Dendreon take $1.9M in profits off the table, Barron's reports
    Dendreon (DNDN) shares more than led on April 14, and have risen more than 1000% in the last six weeks, after the company said its cancer drug, Provenge, met a late-stage study goal, strongly boosting chances of FDA approval. While investors were busy piling into the shares, two executives took $1.9M in profit off the table. On April 20, Principal Accounting Officer Greg Cox exercised 15,313 shares and ultimately sold the shares for $306,260, or $20 a share, for a profit of $189,998. Cox also sold 2,168 shares for $43,360, or $20 a share. On April 14, director Gerardo Canet exercised 109,171 shares and ultimately sold the shares for $2.3M, or $21.40 a share, for a profit of $1.6M. He continues to own 20,956 shares directly. Neither of the insiders owns more than 1% of Dendreon shares outstanding. The transactions were made through 10b5-1 trading plans. It was Cox's first sale of stock and Canet's second, after a small 2007 sale. Only five insiders have sold since 2000. Lon Juricic, president of StreetInsider.com says that he can't blame the insiders for taking some of their money out of the game at this point. Juricic believes the shares will likely hang around the $20 range until more material news about Provenge's FDA approval emerges
    May 01 12:44 pm |Rating: +1 0 |Link to Comment
  • Dendreon's Provenge Is Scientifically Intriguing but Commercially Nonsensical  [View article]
    : Two execs in Dendreon take $1.9M in profits off the table, Barron's reports
    Dendreon (DNDN) shares more than led on April 14, and have risen more than 1000% in the last six weeks, after the company said its cancer drug, Provenge, met a late-stage study goal, strongly boosting chances of FDA approval. While investors were busy piling into the shares, two executives took $1.9M in profit off the table. On April 20, Principal Accounting Officer Greg Cox exercised 15,313 shares and ultimately sold the shares for $306,260, or $20 a share, for a profit of $189,998. Cox also sold 2,168 shares for $43,360, or $20 a share. On April 14, director Gerardo Canet exercised 109,171 shares and ultimately sold the shares for $2.3M, or $21.40 a share, for a profit of $1.6M. He continues to own 20,956 shares directly. Neither of the insiders owns more than 1% of Dendreon shares outstanding. The transactions were made through 10b5-1 trading plans. It was Cox's first sale of stock and Canet's second, after a small 2007 sale. Only five insiders have sold since 2000. Lon Juricic, president of StreetInsider.com says that he can't blame the insiders for taking some of their money out of the game at this point. Juricic believes the shares will likely hang around the $20 range until more material news about Provenge's FDA approval emerges
    May 01 12:44 pm |Rating: 0 -2 |Link to Comment
  • Dendreon's Provenge Is Scientifically Intriguing but Commercially Nonsensical  [View article]
    : Two execs in Dendreon take $1.9M in profits off the table, Barron's reports
    Dendreon (DNDN) shares more than led on April 14, and have risen more than 1000% in the last six weeks, after the company said its cancer drug, Provenge, met a late-stage study goal, strongly boosting chances of FDA approval. While investors were busy piling into the shares, two executives took $1.9M in profit off the table. On April 20, Principal Accounting Officer Greg Cox exercised 15,313 shares and ultimately sold the shares for $306,260, or $20 a share, for a profit of $189,998. Cox also sold 2,168 shares for $43,360, or $20 a share. On April 14, director Gerardo Canet exercised 109,171 shares and ultimately sold the shares for $2.3M, or $21.40 a share, for a profit of $1.6M. He continues to own 20,956 shares directly. Neither of the insiders owns more than 1% of Dendreon shares outstanding. The transactions were made through 10b5-1 trading plans. It was Cox's first sale of stock and Canet's second, after a small 2007 sale. Only five insiders have sold since 2000. Lon Juricic, president of StreetInsider.com says that he can't blame the insiders for taking some of their money out of the game at this point. Juricic believes the shares will likely hang around the $20 range until more material news about Provenge's FDA approval emerges
    May 01 12:42 pm |Rating: +1 -1 |Link to Comment
Comments by Ticker
jamack22's
Comments Stats
4 comments
Rating: -1 (2 - 3 )